Clinical trials: Apixaban
Atrial Fibrillation
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
National Institute of Health and Care Excellence (NICE) guidance recommends anticoagulation for stroke prevention in high risk patients with nonvalvular atrial fibrillation (AF).
- Trial name
- NCT05262322
- Testing
- Edoxaban, Apixaban, Rivaroxaban
- Where
- 8 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company
LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure
SWITCH: Apixaban vs Vitamin K in HM3
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced…
- Conditions
- LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure, Bleeding, Thrombosis; Artery
- Trial name
- NCT07471139
- Testing
- Warfarin, Apixaban
- Where
- United States
- Volunteers
- 460 people
- Sponsor
- Columbia University
Stroke, Atrial Fibrillation
Efficacy and Safety of Oral Anticoagulants Among Thai Octogenarians With Nonvalvular Atrial Fibrillation
A retrospective cohort study of Thai octogenarians with nonvalvular atrial fibrillation (NVAF) initiating apixaban, dabigatran, rivaroxaban or warfarin was conducted in medical school hospital in Thailand.
- Trial name
- NCT04047654
- Testing
- Non vitamin K oral anticoagulants
- Where
- Thailand
- Volunteers
- 327 people
- Sponsor
- Mahidol University
Anticoagulants, Thromboembolism
Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events
Vitamin K antagonists were hampered by several disadvantages, such as the need for frequent monitoring. In this context, new oral anticoagulants (NOACs) have been developed and are now available on the market.
- Conditions
- Anticoagulants, Thromboembolism, Hemorrhage
- Trial name
- Pgp NACO (NCT02103101)
- Testing
- Measurement of Plasma Concentrations of NOACs, Identification of ABCB1 polymorphisms coding for P-gp
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Venous Thromboembolism, Active Cancer
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous…
- Trial name
- NEXT-CAT (NCT07852637)
- Testing
- edoxaban, Apixaban
- Where
- 12 sites in South Korea
- Volunteers
- 2,300 people
- Sponsor
- Samsung Medical Center
Lymphoma, Leukemia
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease
- Trial name
- HEM-DOAC (NCT07270263)
- Testing
- Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk
N/A - Healthy Subjects
Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy Subjects
The purpose of this study is to assess the effects of Apixaban on the Pharmacokinetics (PK) of multiple-dose Digoxin in healthy subjects.
- Trial name
- NCT02262520
- Testing
- Apixaban, Digoxin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism, Multiple Myeloma
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
Patients living with multiple myeloma (MM) have an increased risk of venous thromboembolism (VTE) due to the disease itself and the use of targeted therapies, including immunomodulatory drugs (IMiDs).
- Trial name
- NCT02958969
- Testing
- Apixaban
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Gregory Piazza
Cryptogenic Ischemic Stroke, Patent Foramen Ovale
PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years
To assess whether PFO closure plus antiplatelet therapy is superior to antiplatelet therapy alone and whether oral anticoagulant therapy is superior to antiplatelet therapy to prevent stroke recurrence in patients aged 60 to 80…
- Trial name
- CLOSE-2 (NCT05387954)
- Testing
- Transcatheter PFO closure, Oral Anticoagulant, Direct-Acting, Antiplatelet therapy
- Where
- 42 sites in France
- Volunteers
- 792 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute DVT of Lower Extremity
Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)
The Researchers are studying whether a vascular boot warming program plus standard of care anticoagulation can be a safe and effective method to resolve Deep Vein Thrombosis (DVT) ±Pulmonary Embolism (PE) earlier and prevent…
- Trial name
- NCT03465735
- Testing
- Vascular Boot, Standard of Care
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Atrial Fibrillation
Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
Some people can develop an abnormal heart beat known as "Atrial fibrillation" or "AF" that puts them at risk of developing clots in the heart.
- Trial name
- EMANATE (NCT02100228)
- Testing
- Apixaban, Parenteral heparin and/or oral Vitamin K antagonist
- Where
- 165 sites in United States, Belgium and 10 more
- Volunteers
- 1,500 people
- Sponsor
- Pfizer
Atrial Fibrillation (AF)
Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion
This randomized study was designed to compare two antithrombotic regimens (long-term half-dose apixaban vs long-term aspirin after 45-days of full-dose apixaban) after successful Watchman implantation.
- Trial name
- INTEGRAL (NCT07840365)
- Testing
- Half-Dose of novel OAC, Low-dose ASA
- Where
- United States
- Volunteers
- 234 people
- Sponsor
- Texas Cardiac Arrhythmia Research Foundation
Atrial Fibrillation, Venous Thromboembolism
START-Register: Survey on Anticoagulated Patients Register
This is a phase 4 cohort prospective, open, national, multicentre study that collects data on history of patients treated chronically with anticoagulant drugs, including the novel direct oral anticoagulants (DOACs).
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis
- Trial name
- NCT02219984
- Testing
- Anticoagulants
- Where
- Italy
- Volunteers
- 15,410 people
- Sponsor
- GUALTIERO PALARETI
Liver Cirrhosis
Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis
The aim of this study is to investigate the pharmacokinetic and pharmacodynamic parameters of rivaroxaban and apixaban in patients with compensated liver cirrhosis (Child-Pugh class A and B).
- Trial name
- NCT04874428
- Testing
- Rivaroxaban 10 mg Oral Tablet, Apixaban 2.5 mg Oral Tablet
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Deep Vein Thrombosis
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
Isolated distal DVT (iDDVT) is the most frequent clinical presentation of VTE and is associated with a significant morbidity and risks of long-term complications.
- Trial name
- API-CALF (NCT04981327)
- Testing
- Apixaban 2.5 MG Oral Tablet [ELIQUIS]
- Volunteers
- 1,300 people
- Sponsor
- University Hospital, Geneva
Pulmonary Embolism
The PEERLESS II Study
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
- Trial name
- NCT06055920
- Testing
- FlowTriever System, Anticoagulation Agents
- Where
- 72 sites in United States, Belgium and 6 more
- Volunteers
- 1,200 people
- Sponsor
- Inari Medical
Prevention of Stroke or Systemic Embolism, Atrial Fibrillation
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
Researchers are looking for a better way to treat people with atrial fibrillation (AF) and prevent stroke or systemic embolism (blood clots travelling through the blood stream to plug another vessel).
- Trial name
- OCEANIC-AF (NCT05643573)
- Testing
- Asundexian (BAY2433334), Apixaban
- Where
- 1,069 sites in United States, Argentina and 36 more
- Volunteers
- 14,830 people
- Sponsor
- Bayer
Atrial Fibrillation
Perioperative Anticoagulant Use for Surgery Evaluation Study Part 2 Pilot
The proposed PAUSE-2 RCT study is the logical next step to the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study, which was completed on August 31, 2018.
- Trial name
- PAUSE2rctP (NCT04192552)
- Testing
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Where
- 3 sites in Canada
- Volunteers
- 201 people
- Sponsor
- McMaster University
Non-Valvular Atrial Fibrillation
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating OAC warfarin…
- Trial name
- ARISTOPHANES (NCT03087487)
- Where
- United States
- Volunteers
- 466,991 people
- Sponsor
- Bristol-Myers Squibb
Healthy
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily…
- Trial name
- NCT04593784
- Testing
- Ciraparantag, Point-of-Care Coagulometer (investigational device)
- Where
- 3 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- AMAG Pharmaceuticals, Inc.